浙江震元股份有限公司十一届八次董事会决议公告 证券代码：000705 证券简称：浙江震元 公告编号：2025-035 浙江震元股份有限公司十一届八次董事会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 2、审议通过《关于调整公司第十一届董事会相关专门委员会委员 的议案》 调整周巧米同志为战略委员会委员、薪酬与考核委员会委员。 表决结果：12 票同意，0 票反对，0 票弃权。 3、审议通过《关于向银行申请授信的议案》 公司董事会审议同意公司（含子公司）以信用方式向中国工商银 1 浙江震元股份有限公司十一届八次董事会决议公告 行绍兴分行、浙商银行绍兴越城支行、杭州银行绍兴分行、绍兴银行、 浙江绍兴瑞丰农村商业银行股份有限公司镜湖支行、招商银行绍兴分 行、农业银行绍兴越中支行、宁波银行绍兴分行、中信银行绍兴分行 等 9 家银行申请本金金额不超过人民币 10 亿元的综合授信额度，授信 期限自董事会批准同意日起一年；综合授信额度以银行实际审批的授 信额度为准，具体融资金额视公司实际资金需求和银行审批情况确定； 授信期限内，授信额度可循环 ...

格隆汇8月22日丨浙江震元(000705.SZ)公布2025年半年度报告，上半年公司实现营业收入12.83亿元，同 比下降34.49%；归属于上市公司股东的净利润5626.37万元，同比增长29.27%；归属于上市公司股东的 扣除非经常性损益的净利润3011.73万元，同比下降20.32%；基本每股收益0.17元。 ...

Core Viewpoint - Zhejiang Zhenyuan Co., Ltd. reported a significant decline in revenue for the first half of 2025, with total revenue of approximately 1.28 billion yuan, a decrease of 34.49% compared to the same period last year, primarily due to the exclusion of its subsidiary Zhenyuan Medicine from the consolidated financial statements following a capital increase and share expansion [15][21]. Company Overview - Zhejiang Zhenyuan Co., Ltd. operates in the pharmaceutical industry, focusing on pharmaceutical distribution and manufacturing, including traditional Chinese medicine processing and health products [5][8]. - The company has established a strong brand presence, with its flagship store "Zhenyuan Hall" recognized as a time-honored brand in China, contributing to its competitive advantage in the market [20]. Financial Performance - The company reported a net profit attributable to shareholders of approximately 56.26 million yuan, an increase of 29.27% year-on-year, while the net profit after deducting non-recurring gains and losses was about 30.12 million yuan, a decrease of 20.32% [15][21]. - The total assets of the company at the end of the reporting period were approximately 2.96 billion yuan, down 13.55% from the previous year [15]. Business Segments - The pharmaceutical distribution segment includes wholesale and retail operations, with Zhenyuan Medicine successfully attracting strategic investment from China Resources Pharmaceutical Group, enhancing its market competitiveness [8][16]. - The retail segment, led by Zhenyuan Medicine Chain Co., Ltd., has been recognized as a top 100 pharmaceutical chain enterprise in China, with a focus on integrating online and offline services [9][10]. Industry Trends - The pharmaceutical industry is undergoing structural changes, with a shift from price reduction to ensuring supply and quality, driven by national policies aimed at improving healthcare services [6][7]. - The integration of digital tools and online services in the pharmaceutical retail sector is becoming a mainstream trend, enhancing operational efficiency and customer service [6][12]. Research and Development - Zhenyuan Pharmaceutical has a strong focus on R&D, with multiple certifications and patents, and is recognized as a national high-tech enterprise [14][21]. - The company is actively involved in the development of synthetic biology technologies and has established collaborations with leading research institutions to enhance its product offerings [14][21].

证券代码：000705 证券简称：浙江震元 公告编号：2025-036 浙江震元股份有限公司 浙江震元股份有限公司 董事长：吴海明 二〇二五年八月二十一日 浙江震元 2025 年半年度报告摘要 一、重要提示 本半年度报告摘要来自半年度报告全文，为全面了解本公司的经营成果、财务状 况及未来发展规划，投资者应当到证监会指定媒体仔细阅读半年度报告全文。 所有董事均已出席了审议本报告的董事会会议。 非标准审计意见提示 □ 适用 ? 不适用 董事会审议的报告期普通股利润分配预案或公积金转增股本预案 □ 适用 ? 不适用 公司计划不派发现金红利，不送红股，不以公积金转增股本。 董事会决议通过的本报告期优先股利润分配预案 □ 适用 ? 不适用 二、公司基本情况 股票简称 浙江震元 股票代码 000705 股票上市交易所 深圳证券交易所 联系人和联系方式 董事会秘书 证券事务代表 姓名 张誉锋 蔡国权 浙江省绍兴市越城区稽山街道延安 浙江省绍兴市越城区稽山街道延安 办公地址 东路 558 号 东路 558 号 电话 0575-85746658 0575－85139563 电子信箱 000705@zjzy.com 000705 ...

Financial Performance - The company's revenue for the reporting period was approximately ¥1.28 billion, a decrease of 34.49% compared to ¥1.96 billion in the same period last year[19]. - Net profit attributable to shareholders increased by 29.27% to ¥56.26 million from ¥43.52 million year-on-year[19]. - The net cash flow from operating activities significantly dropped by 95.36% to ¥6.33 million, down from ¥136.35 million in the previous year[19]. - Basic and diluted earnings per share rose by 30.77% to ¥0.17 from ¥0.13 in the same period last year[19]. - Total assets decreased by 13.55% to approximately ¥2.96 billion from ¥3.42 billion at the end of the previous year[19]. - The net assets attributable to shareholders increased by 2.62% to ¥2.01 billion from ¥1.96 billion at the end of the previous year[19]. - The total profit amounted to 63.41 million yuan, reflecting a year-on-year increase of 7.05%[49]. - The company reported a significant increase in cash flow from financing activities, which rose by 117.51% to approximately ¥173.22 million, driven by capital injections into Zhenyuan Pharmaceutical[62]. Business Operations - The company operates in the pharmaceutical industry, focusing on drug distribution and production, including raw materials and traditional Chinese medicine processing[27]. - The company expanded its retail network to 177 stores, covering a total area of 31,723.07 square meters[38]. - The company’s subsidiary, Zhejiang Zhenyuan Pharmaceutical Chain Co., Ltd., was recognized as one of the top 100 pharmaceutical retail enterprises in China, ranking 62nd in the value list of Chinese pharmacies[35]. - The company’s innovative online and offline integration model, "Internet Hospital + Pharmaceutical Retail," was officially launched, enhancing operational efficiency and service quality[35]. - The company’s wholesale business has established long-term partnerships with numerous well-known pharmaceutical companies, enhancing its market competitiveness[35]. - The pharmaceutical manufacturing segment generated approximately ¥285.85 million, accounting for 22.27% of total revenue, with a year-on-year decline of 22.49%[65]. - The pharmaceutical commercial segment contributed approximately ¥997.42 million, representing 77.73% of total revenue, with a year-on-year decrease of 37.27%[65]. Strategic Initiatives - The company plans not to distribute cash dividends or issue bonus shares[7]. - The company is positioned to benefit from the structural transformation in the pharmaceutical industry, with a focus on high-quality innovative drugs and international market expansion[30]. - The company is actively participating in the digital transformation of the pharmaceutical retail sector, leveraging digital tools to enhance service quality and operational activity[34]. - The company is committed to the high-quality development of traditional Chinese medicine, aligning with national policies to modernize and industrialize the sector[33]. - The company plans to introduce strategic investors and optimize its business structure to mitigate risks from industry policy changes[81]. Research and Development - The approval of 43 innovative drugs in the first half of 2025 marked a 59% year-on-year increase, indicating a strong growth trajectory in the innovative drug sector[30]. - The pharmaceutical subsidiary obtained 1 patent authorization and filed for 1 new patent during the reporting period, totaling 25 authorized patents[48]. - The company has advanced the construction of the Zhenyuan Biological project, expected to commence production in Q3 2025[51]. Financial Position - Cash and cash equivalents at the end of the reporting period amounted to ¥512,513,917.05, representing 17.34% of total assets, an increase of 1.27% compared to the previous year[67]. - Accounts receivable decreased by 9.18% to ¥328,109,404.08, accounting for 11.10% of total assets, primarily due to the completion of a capital increase by a subsidiary[67]. - Inventory decreased by 3.26% to ¥523,686,513.35, representing 17.72% of total assets, attributed to the exclusion of a subsidiary from the consolidated financial statements[67]. - The company reported a significant decrease in total investments to ¥0.00 from ¥209,100,000.00 in the previous year, indicating a 100% reduction[72]. - Long-term equity investments increased by 3.03% to ¥89,866,825.82, now accounting for 3.04% of total assets[67]. Risk Management - The company has established a risk management mechanism to address project investment risks and ensure expected returns[84]. - The company has noted potential risks to the economic benefits of the Zhenyuan Biological project due to macroeconomic changes, intense market competition, and product price fluctuations[115]. Corporate Governance - The company did not distribute cash dividends or issue bonus shares during the reporting period[87]. - The company has not implemented any stock incentive plans or employee shareholding plans during the reporting period[87]. - The company reported no significant related party transactions during the reporting period[99]. - There were no asset or equity acquisitions or sales related party transactions during the reporting period[98]. - The company did not engage in any joint external investment related party transactions during the reporting period[99]. Environmental and Social Responsibility - The company provided free health services to over 3,000 citizens during the reporting period[89]. - The company has been included in the environmental information disclosure list, with one subsidiary reporting environmental data[88].

合 并 资 产 负 债 表 2025年6月30日 会合01表 | 编制单位：浙江震元股份有限公司 | | | | | 单位：人民币元 | | --- | --- | --- | --- | --- | --- | | 资 产 | 期末数 | 期初数 | 负债和所有者权益 | 期末数 | 期初数 | | | | | (或股东权益) | | | | 流动资产： | | | 流动负债： | | | | 货币资金 | 512,513,917.05 | 549,426,935.55 | 短期借款 | 20,007,555.56 | 249,193,127.55 | | 结算备付金 | | | 向中央银行借款 | | | | 拆出资金 | | | 拆入资金 | | | | 交易性金融资产 | | | 交易性金融负债 | | | | 衍生金融资产 | | | 衍生金融负债 | | | | 应收票据 | | | 应付票据 | 58,738,540.36 | 182,381,426.61 | | 应收账款 | 328,109,404.08 | 693,387,618.76 | 应付账款 | 328,736,798.03 | 5 ...

浙江震元股份有限公司 2025年1-6月非经营性资金占用及其他关联资金往来情况汇总表 | 编制单位：浙江震元股份有限公司 | | | | | | | | | | 单位：万元 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 非经营性资金占用 | 资金占用方名称 | 占用方与上市公司的 | 上市公司核算的会计 | 2025年初占用资金余 | 2025年1-6月占用累 | 2025年1-6月占用资 | 2025年1-6月偿还累 | 2025年6月末占用资 | 占用形成原因 | 占用性质 | | | | 关联关系 | 科目 | 额 | 计发生金额(不含利 | 金的利息(如有) | 计发生金额 | 金余额 | | | | 控股股东、实际控制人及 | | | | | 息) | | | | - | | | 其附属企业 | | | | | | | | | - | | | 小计 | — | — | — | - | - | - | - | | - | | | 前控股股东、实际控制人 | | | | | | | | | - | | | ...

浙江震元股份有限公司 2025年半年度财务报告 （未经审计） 二〇二五年八月二十一日 合 并 资 产 负 债 表 2025年6月30日 编制单位：浙江震元股份有限公司 单位：人民币元 会合01表 | 资 产 | 期末数 | 期初数 | 负债和所有者权益 (或股东权益) | 期末数 | 期初数 | | --- | --- | --- | --- | --- | --- | | 流动资产： | | | 流动负债： | | | | 货币资金 | 512,513,917.05 | 549,426,935.55 | 短期借款 | 20,007,555.56 | 249,193,127.55 | | 结算备付金 | | | 向中央银行借款 | | | | 拆出资金 | | | 拆入资金 | | | | 交易性金融资产 | | | 交易性金融负债 | | | | 衍生金融资产 | | | 衍生金融负债 | | | | 应收票据 | | | 应付票据 | 58,738,540.36 | 182,381,426.61 | | 应收账款 | 328,109,404.08 | 693,387,618.76 | 应付账款 | 328 ...

浙江震元股份有限公司 2025 年第一次临时股东大会决议公告 证券代码：000705 证券简称：浙江震元 公告编号：2025-034 浙江震元股份有限公司 2025 年第一次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 一、会议召开和出席情况 （1）会议召开时间 现场会议召开的时间为：2025 年 8 月 20 日 15:00 开始 网络投票的时间为：通过深圳证券交易所交易系统进行网络投票的时间为： 互联网投票系统投票的具体时间为：2025 年 8 月 20 日 9:15-15:00。 （2）现场会议召开的地点：公司 331 会议室（绍兴市延安东路 558 号） （3）会议召开的方式：现场表决和网络投票相结合的方式 （4）召集人：公司董事会 （5）主持人：董事长吴海明先生 本次会议符合有关法律、行政法规、部门规章、规范性文件和公司章程的规 定。 参加本次股东大会现场会议和网络投票的股东及股东代表共 368 人，代表股 份 93,571,677 股，占公司有表决权股份总数的 28.0051%。其中参加本次股东大会 现场投票的股 ...

上海市锦天城律师事务所 关于浙江震元股份有限公司 法律意见书 地址：上海市浦东新区银城中路 501 号上海中心大厦 11/12 楼 电话：021-20511000 传真：021-20511999 邮编：200120 上海市锦天城律师事务所 法律意见书 上海市锦天城律师事务所 关于浙江震元股份有限公司 法律意见书 致：浙江震元股份有限公司 上海市锦天城律师事务所（以下简称"本所"）接受浙江震元股份有限公司 （以下简称"公司"）委托，就公司召开 2025 年第一次临时股东大会（以下简 称"本次股东大会"）的有关事宜，根据《中华人民共和国公司法》（以下简称 《公司法》）、《上市公司股东会规则》等法律、法规、规章和其他规范性文件 以及《浙江震元股份有限公司章程》（以下简称《公司章程》）的有关规定，出 具本法律意见书。 为出具本法律意见书，本所及本所律师依据《律师事务所从事证券法律业务 管理办法》和《律师事务所证券法律业务执业规则（试行）》等规定，严格履行 了法定职责，遵循了勤勉尽责和诚实信用原则，对本次股东大会所涉及的相关事 项进行了必要的核查和验证，核查了本所认为出具该法律意见书所需的相关文件、 资料，并参加了公司 ...